Original Investigation | Clinical Sciences

Retinal Vasoproliferative Tumors in 6 Patients With Neurofibromatosis Type 1

Jerry A. Shields, MD1; Marco Pellegrini, MD1; Swathi Kaliki, MD1,2; Arman Mashayekhi, MD1; Carol L. Shields, MD1
[+] Author Affiliations
1The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
2The Ocular Oncology Service, L. V. Prasad Eye Institute, Hyderabad, India
JAMA Ophthalmol. 2014;132(2):190-196. doi:10.1001/jamaophthalmol.2013.6281.
Text Size: A A A
Published online

Importance  Retinal vasoproliferative tumors (RVPTs) are an important ocular finding in patients with neurofibromatosis type 1 (NF1), and early detection of this association and prompt initiation of treatment may prevent vision loss and blindness in affected patients.

Objectives  To describe the clinical findings of RVPTs in patients with NF1 and to underscore the risk of severe vision loss in such patients.

Design, Setting, and Patients  We performed a retrospective medical record review of 6 patients with RVPTs and NF1 treated at the Ocular Oncology Service, Wills Eye Hospital.

Main Outcomes and Measures  The demographics, clinical features, clinical course, and outcomes of the 6 patients with RVPTs were recorded.

Results  Of 275 patients with RVPTs, 6 (2.2%) had NF1. At the time of diagnosis of RVPT, the median patient age was 12 years (range, 9-36 years). Visual acuity was variable, ranging from 6/7.5 to light perception on initial presentation to the oncology service. The RVPT was located between the equator and ora serrata in all patients. The mean basal tumor diameter was 11 mm, and the mean tumor thickness was 4 mm. Associated features included subretinal fluid (n = 6), subretinal exudation (n = 6), epiretinal membrane (n = 3), retinal hemorrhage (n = 2), vitreous hemorrhage (n = 1), retinal neovascularization (n = 1), and cystoid macular edema (n = 1). Fluorescein angiography revealed early hyperfluorescence and late staining and leakage of each RVPT. B-scan ultrasonography revealed acoustic solidity of the lesion. Initial management included cryotherapy, intravitreal injection of bevacizumab, plaque radiotherapy, and primary enucleation in 1 patient because of painful neovascular glaucoma.

Conclusions and Relevance  We found that RVPTs can develop in patients with NF1 and can cause exudative retinopathy, vitreous hemorrhage, and visual loss. Patients with NF1 should undergo periodic ophthalmic examination for detection and treatment of this tumor. It is important to recognize the occurrence of RVPT in patients with NF1 because knowledge of this association and early treatment can prevent severe loss of vision in affected patients.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours


Place holder to copy figure label and caption
Figure 1.
Imaging of Retinal Vasoproliferative Tumors (RVPTs) in Patients With Neurofibromatosis Type 1

Inferior RVPT (A) and extensive exudation in the posterior fundus, confirmed on fluorescein angiogram (B) and B-scan ultrasonogram (C) (patient 1). D, Superotemporal RVPT and inferior exudative retinal detachment (patient 2). Note that the macula is normal. Fluorescein angiogram (E) and B-scan ultrasonogram (F) are noted. Inferotemporal RVPT (G) with extensive exudative retinal detachment in the posterior fundus, confirmed on fluorescein angiogram (H) and B-scan ultrasonogram (I) (patient 3).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Clinical Variations of Retinal Vasoproliferative Tumors (RVPTs) in Patients With Neurofibromatosis Type 1

A, Superior RVPT seen through vitreous blood in patient 4. B, The lesion was treated with cryotherapy with complete regression and visual acuity of 6/9 at 17-year follow-up. C, Neovascular glaucoma required a shunt valve. D, Prosthetic right eye after enucleation for neovascular glaucoma when the patient was 5 years old (patient 5). E, Tracheostomy tube placed for tracheal compression from subcutaneous neurofibroma. F, Hazy view of RVPT (VPT) through vitreous hemorrhage. Note the surrounding exudation (Exudation). The lesion was treated with cryotherapy. After 11 years, visual acuity was 6/7.5, and the tumor was completely controlled. G, The right eye had neovascular glaucoma and vascular congestion from untreated RVPT with retinal detachment. H, The left eye had iris Lisch nodules. I, The abdominal skin had numerous neurofibromas.

Graphic Jump Location




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles